RTP Mobile Logo
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

Breast cancer remains the most frequently diagnosed cancer in women, and in 2014 in the United States alone the disease culminated in an estimated 232,670 new cases and 40,000 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. The indication and/or utility of these local and systemic treatment options is largely based on a number of prognostic and predictive risk factors present within the patient or her tumor at the time of diagnosis. In fact, as the field of oncology is challenged to improve the precision with which it therapeutically targets malignant cells, biomarker-driven treatment algorithms have become the “norm” for many tumor types, including breast cancer.

These proceedings from a CME symposium during the 37th annual San Antonio Breast Cancer Symposium explore the most significant therapeutic advances during the previous year by using the perspectives of leading breast cancer experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists integrate these findings into best-practice disease management strategies.


  • Appreciate the similarities and differences between existing genomic assays, and use this information to select an appropriate platform or platforms to assess risk and individualize therapy for patients with invasive and noninvasive early breast cancer.
  • Develop an evidence-based algorithm for the initial and long-term treatment of localized hormone receptor-positive pre- and postmenopausal breast cancer.
  • Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-overexpressing early breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing, recently approved and investigational targeted treatments.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive breast cancer, including the use of endocrine, biologic and chemotherapeutic agents.
  • Apply the results of current clinical research to the selection and sequencing of available therapeutics for patients with localized and advanced triple-negative breast cancer.
  • Recall emerging research data with next-generation sequencing, and determine the clinical and/or research application for patients with metastatic breast cancer.
  • Counsel appropriately selected patients about participation in ongoing breast cancer clinical research.

CME credit is no longer available for this issue


CME credit is no longer available for this issue

This CME activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina

Advisory Committee: Amgen Inc, Roche Laboratories Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Contracted Research: Celgene Corporation, Genentech BioOncology; Speakers Bureau: Genomic Health Inc.

Adam M Brufsky, MD, PhD
Professor of Medicine
University of Pittsburgh
Associate Director for Clinical Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief
University of Pittsburgh
Department of Medicine
Division of Hematology/Oncology
Pittsburgh, Pennsylvania

Consulting Agreements: Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

Angelo Di Leo, MD, PhD
Head of Sandro Pitigliani Medical Oncology Unit
Department of Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy

Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Speakers Bureau: Genomic Health Inc, Sanofi.

Kathy D Miller, MD
Co-Director, IU Simon Cancer Center
Breast Cancer Program
Ballvé-Lantero Scholar in Oncology
Professor of Medicine Division of Hematology/Oncology
The Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Contracted Research: Astellas Scientific and Medical Affairs Inc, Genentech BioOncology, Roche Laboratories Inc.

Eric P Winer, MD
Thompson Chair in Breast Cancer Research
Chief, Division of Women’s Cancers
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Contracted Research: Genentech BioOncology.

MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Foundation Medicine, Genentech BioOncology, Genomic Health Inc and Lilly.

Hardware/Software Requirements:
A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

Adobe Flash Player 10.2 plug-in or later

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Last review date: April 2015
Expiration date
: April 2016